Search documented disagreements and product cautions across the local library. Compare complete source versions on the drug page before choosing a regimen.
Search medication names and documented issues only. Do not enter patient information. This directory submits search filters to the server; the within-drug text finder remains a separate local feature.
A difference is not always a contradiction
Compare indication, formulation, route, population, renal method, dialysis conditions and source date. A safety update or source-quality failure is not an alternative dose. These notes are not independent clinical approval, and sources are not ranked or averaged.
New renal toxicity is not a baseline starting-dose table
KYPROLIS renal hold/restart criteria depend on creatinine change, clearance, causality and the selected oncology dose level; HD administration follows dialysis.
What to reconcile
Do not calculate one universal renal maintenance dose or restart from an unrelated oncology regimen. Preserve the causality and recovery conditions.
1 source identities and dates
GlobalRPh RX List - KYPROLIS
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Carfilzomib treatment-emergent renal toxicity; dose-level reduction depends on the selected oncology regimen.
Total daily doses, indexed eGFR and metabolic indication must stay together
CARBAGLU has separate renal tables for NAGS deficiency and acute PA/MMA-associated hyperammonemia. The numbers are total daily doses, not doses per administration.
What to reconcile
Confirm the indication, indexed eGFR, actual weight/BSA, dose splitting and rounding before prescribing; no ESRD dose is inferred.
1 source identities and dates
Carglumic acid - CARBAGLU tablets for suspension
DailyMed / Recordati Rare Diseases Inc. | Source revision: 1/2024 CARBAGLU 200 mg tablets for suspension. Match NAGS deficiency versus PA/MMA and acute versus chronic hyperammonemia.
Dialyzability does not supply a replacement-dose schedule
The source provides caution and removal information, not a tested renal dosing table.
What to reconcile
Do not invent a supplemental dose or classify the evidence gap as no adjustment.
1 source identities and dates
GlobalRPh RX List - SOMA
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. SOMA single-ingredient oral carisoprodol; not aspirin- or codeine-containing combinations.
A numeric stop threshold does not cancel a broader restriction
Both retrieved sources retain broad renal non-administration wording alongside a numeric discontinuation threshold. The official document also has conflicting date fields.
What to reconcile
Reconcile the current exact product and oncology protocol; do not manufacture a permissive renal ladder from the threshold.
2 source identities and dates
GlobalRPh RX List - BiCNU
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. BiCNU carmustine for intravenous infusion; not an intracranial implant. The retrieved label is a dated product snapshot, not proof of current availability.
DailyMed / Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | Source revision: Highlights 11/2021; manufacturer text 10/2020; SPL effective 2023-11-21 BiCNU carmustine for intravenous infusion; not an intracranial implant. The retrieved label is a dated product snapshot, not proof of current availability.
A creatinine-only dosing shortcut is inappropriate for this evidence
The product requires DMD-specific renal surveillance rather than a validated creatinine-based reduction table.
What to reconcile
Use the dated monitoring card, including urine-collection timing and assay interference precautions; do not infer a renal dose.
2 source identities and dates
GlobalRPh RX List - AMONDYS 45
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. AMONDYS 45 intravenous casimersen in Duchenne muscular dystrophy with an exon-45-skipping-amenable mutation; renal monitoring is not a creatinine-only dose table.
DailyMed / Sarepta Therapeutics, Inc. | Source revision: 1/2026 AMONDYS 45 intravenous casimersen in Duchenne muscular dystrophy with an exon-45-skipping-amenable mutation; renal monitoring is not a creatinine-only dose table.
Printed indexed CrCl and undefined ESRD dosing need separate checks
The source uses indexed clearance units and reports dialysis removal without an established ESRD regimen.
What to reconcile
Do not silently relabel the units or extrapolate a dialysis dose; official-product reconciliation remains pending.
1 source identities and dates
GlobalRPh RX List - SPECTRACEF
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. SPECTRACEF oral cefditoren pivoxil; selected historical product guidance, not proof of current US commercial availability.
Daily post-HD timing is not the same as post-HD-only dosing
Label and institutional sources include daily dosing and post-dialysis-only schedules. Their indication, dialysis frequency, infusion, and exposure assumptions differ.
What to reconcile
Select one complete locally approved regimen; do not add a daily dose on top of a post-HD-only schedule.
3 source identities and dates
GlobalRPh RX List - Maxipime
GlobalRPh-hosted RX List | Source revision: Revision date not established in selected retrieval. Adult IV cefepime. Columns below correspond to the original usual regimen, not interchangeable infection choices.
UCSF Infectious Diseases Management Program | Source revision: Revision date not stated in the reviewed page. Adult IV cefepime; short infusion, selected extended infusion, IHD and CVVHD.
Stanford Health Care Antimicrobial Safety and Sustainability | Source revision: Current retrieved guide; see source document for revision history. Adults; cefepime IV. Guide page 2, IHD/CRRT columns.
Different HD schedules remain source-specific, not interchangeable
The MAXIPIME mirror uses daily maintenance; UCSF describes a post-HD strategy and a separate unstable-schedule alternative.
What to reconcile
Resolve indication, dialysis timing and local specialist protocol before selecting a regimen; do not average or mix schedules.
2 source identities and dates
GlobalRPh RX List - MAXIPIME
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Single-agent intravenous cefepime in adults. Label-mirror schedules and UCSF institutional regimens must retain their distinct context.
UCSF Infectious Diseases Management Program | Source revision: Source revision date not established in selected retrieval. Single-agent intravenous cefepime in adults. Label-mirror schedules and UCSF institutional regimens must retain their distinct context.
CRRT effluent guidance is not an intermittent-HD dose table
The selected official and mirror tables agree. Their CRRT guidance is explicitly initial and depends on effluent rather than a CrCl band.
What to reconcile
Confirm modality and L/hour effluent, then reassess residual function and clinical status; do not interpolate a new algorithm.
2 source identities and dates
GlobalRPh RX List - FETROJA
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. FETROJA intravenous cefiderocol in adults; renal function, intermittent HD and CRRT effluent are separate dosing contexts.
DailyMed / Shionogi Inc. | Source revision: 3/2026 (printed highlights); DailyMed updated 2026-02-24 FETROJA intravenous cefiderocol in adults; renal function, intermittent HD and CRRT effluent are separate dosing contexts.
The recovered institutional page has different printed boundaries
The official label uses CrCl >=120; UCSF prints >120 beside 60-119. The upper effluent band is >=4.1 L/hour in the label versus >4 in UCSF.
What to reconcile
For exactly CrCl 120 the official label is explicit. Preserve the institutional discrepancy and seek clarification for effluent values between printed bands; do not interpolate. This is a wording/boundary comparison, not evidence of different clinical outcomes.
2 source identities and dates
Cefiderocol - FETROJA adult intravenous therapy
DailyMed / Shionogi Inc. | Source revision: 3/2026 (highlights); DailyMed updated 2026-02-24 Adult cefiderocol IV; distinguish non-dialysis CrCl from intermittent HD and CRRT effluent. Institutional protocols remain separately attributed.
UCSF Infectious Diseases Management Program | Source revision: Source revision date not established in selected retrieval. Adult cefiderocol IV; distinguish non-dialysis CrCl from intermittent HD and CRRT effluent. Institutional protocols remain separately attributed.
One-hour labeling versus institutional extended infusion
The RX label table uses a one-hour infusion. The UCSF protocol uses a three-hour infusion. Both also separate urinary/intra-abdominal infection from pneumonia/severe infection.
What to reconcile
Keep the selected source dose, indication, renal band, loading instruction and infusion duration together.
2 source identities and dates
GlobalRPh RX List - Zerbaxa
GlobalRPh-hosted RX List | Source revision: Revision date not established in selected retrieval. Adult IV combined doses; cUTI/cIAI and HABP/VABP columns remain separate.
UCSF Infectious Diseases Management Program | Source revision: Revision date not stated in the reviewed page. Adults; ceftolozane/tazobactam total combination doses IV; ID/stewardship restricted.
Pediatric renal guidance changed after the RX mirror
The older mirror lacks the age-specific renal regimens now supplied by the May 2026 label.
What to reconcile
Use the new pediatric card for ages two and older; verify indication, pediatric eGFR, weight caps and infusion time. Do not use adult Cockcroft-Gault bands as pediatric instructions.
2 source identities and dates
GlobalRPh RX List - ZERBAXA
GlobalRPh-hosted RX List | Source revision: May 2022 Adult IV ZERBAXA only in this older mirror; pediatric guidance is in the separate 2026 label card.
DailyMed / Merck Sharp & Dohme LLC | Source revision: May 2026 Pediatric ZERBAXA age 2 to below 18 with renal impairment; May 2026 label, Table 4. Doses are total ceftolozane+tazobactam.
Label maximum differs from institution-specific bacteremia dosing
The KEFLEX renal table caps the daily dose in moderate impairment. UCSF uses a different high-dose strategy for selected gram-negative bloodstream infection; Stanford also has a distinct HD regimen.
What to reconcile
The indication and regimen must stay together. Do not average the doses or relabel the bloodstream-infection schedule as a general renal dose.
3 source identities and dates
GlobalRPh RX List - Keflex
GlobalRPh-hosted RX List | Source revision: Revised October 2015 Adults and patients at least 15 years old; oral cephalexin label table.
UCSF Infectious Diseases Management Program | Source revision: Revision date not stated in the reviewed page. Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Label daily cap versus indication-specific institutional bloodstream doses
KEFLEX limits total daily dose to 1 g at CrCl 30-59 and has insufficient HD adjustment information. UCSF uses higher selected Gram-negative bloodstream-infection doses and supplies an intermittent-HD row.
What to reconcile
Assess infection eligibility, organism susceptibility, patient setting and institutional policy. Keep the complete institutional regimen separate from the label; do not transfer the bloodstream schedule to routine cystitis or children.
2 source identities and dates
GlobalRPh RX List - KEFLEX
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Oral KEFLEX; renal table applies to adults and pediatric patients at least 15 years old.
UCSF cephalexin - selected bloodstream-infection and dialysis rows
UCSF Infectious Diseases Management Program | Source revision: Source revision date not established in selected retrieval. Adult institutional oral therapy for selected gram-negative bloodstream infection; eligibility not established by the renal table alone.
IV cetirizine is not the oral levocetirizine renal schedule
The selected QUZYTTIR IV label does not require a renal dose change in the stated populations, but use below age 6 with renal or hepatic impairment is not recommended. Oral levocetirizine has a separate renal schedule and exclusions.
What to reconcile
Match the ingredient, route, age and acute-urticaria indication. Do not transfer an oral schedule to this IV product or turn a pediatric not-recommended statement into an adult contraindication.
1 source identities and dates
QUZYTTIR - IV cetirizine, renal and age-specific instructions
DailyMed | Source revision: March 2026 QUZYTTIR IV cetirizine for acute urticaria. Renal guidance applies with the explicit under-6-year exclusion.
Unstudied renal PK must not appear as no adjustment needed
The official and mirror sections agree on an evidence gap, not on an established CKD regimen.
What to reconcile
Keep renal and dialysis uncertainty visible, with stone and hydration precautions.
2 source identities and dates
GlobalRPh RX List - EVOXAC
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. EVOXAC oral cevimeline capsules for dry-mouth symptoms in Sjogren syndrome; kidney-stone precautions and renal PK gaps are distinct.
Only documented issues are searchable here. Absence of a note is not agreement. A label mirror and the original label are not independent corroboration, and a source's retrieval date is not its revision date.